Elpis Biopharmaceuticals

Executive Summary

Elpis Biopharmaceuticals is a clinical-stage biopharmaceutical company pioneering next-generation bispecific armored CAR-T therapies for solid tumors. Founded in 2018 and headquartered in Cambridge, MA, the company leverages proprietary platforms including multi-mechanism armor technology and bispecific targeting antibodies to overcome tumor heterogeneity and the immunosuppressive tumor microenvironment. Elpis is currently in the pre-clinical stage, advancing toward IND-enabling studies for its lead candidate. The company's differentiated approach positions it to address key limitations of current CAR-T therapies in solid tumors, potentially unlocking a significant market opportunity. While still early-stage, Elpis's innovative platform and focus on armored, bispecific constructs could yield first-in-class therapies if successfully translated to the clinic.

Upcoming Catalysts (preview)

• Q2 2026IND Filing for Lead CAR-T Candidate40% success
• Q3 2026Presentation of Preclinical Data at Major Conference80% success
• Q4 2026Series A or B Financing Round60% success